ENGOT-OV16/NOVA Phase 3 trial

November 1, 2019

Zejula Maintenance Increases Time Without Symptoms or Toxicity in Recurrent OC Patients, Study Says

News

Taking Zejula (niraparib) as a maintenance therapy may increase time without symptoms or toxicities from treatment in women with recurrent ovarian cancer, a new study found. These results suggest that ... Read more

November 9, 2018

Zejula Leads to Fewer Side Effects Than Previously Reported, Real-world Study Suggests

News

Ovarian cancer patients who receive Zejula (niraparib) after responding to platinum-based chemotherapy experience fewer adverse effects in a real-world setting than was reported in a Phase 3 clinical trial, a study ... Read more

June 20, 2018

Zejula Added to UK’s Cancer Drugs Fund for Recurrent, Platinum-sensitive Ovarian Cancer

News

Women in England and Wales with recurrent, platinum-sensitive ovarian cancer can now access Zejula (niraparib) through the Cancer Drugs Fund (CDF) after a recommendation by the U.K.’s National Institute for Health and Care ... Read more

April 9, 2018

Zejula-Keytruda Combo Shows Promise in Certain Ovarian Cancer Patients in Clinical Trial

News

A combination of Zejula (niraparib) and Keytruda (pembrolizumab) reduced tumor size in one out of four difficult-to-treat ovarian cancer patients, Tesaro‘s Phase 1/2 trial revealed. The 25% response rate seen in ... Read more

December 20, 2017

Tesaro’s Zejula for Recurrent Ovarian Cancer Now Available in Germany

News

Zejula (niraparib), an oral therapy for patients with recurrent ovarian cancer, is now available in Germany, according to Tesaro, the biopharma that developed the therapy. “The introductions of Zejula in Germany and ... Read more

December 1, 2017December 1, 2017

European Commission Approves Tesaro’s Zejula as Maintenance Therapy for Ovarian Cancer

News

The European Commission has approved Tesaro‘s Zejula (niraparib) as a maintenance treatment for ovarian cancer, with or without BCRA mutations, in women who have shown a complete or partial response ... Read more

October 2, 2017

Tesaro Shares Multitude of Ovarian Cancer Treatment Findings at Madrid Conference

News

Half of ovarian cancer patients in a small study responded to a combination of Tesaro’s Zejula and Genentech’s Avastin, according to a presentation Tesaro made at the European Society of Medical Oncology (ESMO) 2017 ... Read more

September 18, 2017

Tesaro’s Ovarian Cancer Therapy Zejula Moves One Step Closer to EU Approval

News

The European Medicine Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Tesaro‘s Zejula (niraparib) as a maintenance therapy for recurrent platinum-sensitive ovarian ... Read more

May 31, 2017

Zejula Continues to Show Promise in Recurrent Ovarian Cancer Patients

News

Tesaro will present three abstracts with results from the ENGOT-OV16/NOVA trial evaluating the effectiveness of Zejula (niraparib) in patients with recurrent ovarian cancer at the upcoming 2017 American Society of Clinical ... Read more

October 31, 2016

European Medicines Agency Will Review Marketing Application for Niraparib to Treat Ovarian Cancer

News

The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Application (MAA) of niraparib for the treatment of platinum-sensitive ovarian cancer patients, according to Tesaro, the product manufacturer. ... Read more